Long-term survival in a young woman with recurrent HER2-positive breast cancer.

Lungosopravvivenza in giovane donna affetta da tumore mammario recidivato HER2-positivo

Authors

  • Gianluca Cotroneo UOC Oncologia Medica, ASST Bergamo Est, Seriate (BG) - Italy

DOI:

https://doi.org/10.19156/abtpn.2018.0035

Keywords:

Lapatinib, Trastuzumab, Pertuzumab, Breast cancer, Long-term survival

Abstract

We report the case of a patient with HER2-positive breast cancer relapsing after 7 years from diagnosis with a HER2-positive tumor recurrence, treated with anti-HER2 drugs (pertuzumab, trastuzumab and lapatinib) associated to radiotherapy and/or chemotherapy. These therapeutic strategies allowed satisfactory disease control after about 4 years from recurrence (Oncology).

Downloads

Download data is not yet available.

Downloads

Published

2018-06-27

How to Cite

Cotroneo, G. (2018). Long-term survival in a young woman with recurrent HER2-positive breast cancer.: Lungosopravvivenza in giovane donna affetta da tumore mammario recidivato HER2-positivo. AboutOpen, 4(1), 29–31. https://doi.org/10.19156/abtpn.2018.0035

Issue

Vol. 4 No. 1 (2018): January - December 2018

Section

Case report

Metrics

Crossref
Scopus
Google Scholar
Europe PMC